Biodiscovery case in Mongolia
In the ravines and valleys of western provinces of Mongolia, grows a special plant, Comarum Salesovianum, that locals call the “sneezing plant”, as any human or animal will sneeze if they smell it.
For generations, Mongolians have known the antibacterial properties of the sneezing plant. This traditional knowledge encouraged the Bioorganic Chemistry and Pharmacognosy Laboratory of the National University of Mongolia (NUM) to join forces with the “Monos” Medical institute (a private institute owned by the Monos Group), the National Center for Dermatology of Mongolia (a public institute) and the Tohoku Pharmaceutical University of Japan, to conduct a research and development of a “phytoacne” cream.
The cream is being produced and sold by the “Mongolia Bio Products – Lab”, a start-up company of the NUM. Sales of the product started at the NUM brand shop in march 2018, and later on, Monos pharmacies have started selling it, having to pay royalties to the start-up company.
This biodiscovery case has both monetary and non-monetary benefits, as per the Nagoya Protocol and Bonn Guidelines. As part of the partnership, the Bioorganic Chemistry and Pharmacognosy Laboratory of NUM has also received non-monetary benefits such as new analytics equipment.
This biodiscovery project, supported by the UNDP-GEF Global ABS Project, aims to achieve several Sustainable Development Goals (SDG). Among them, SDG 15 (Life on Land), SDG 9 (Industry, Innovation and Infrastructure) and SDG 8 (Decent work and Economic Growth).
Learn more on this biodiscovery case here.
View more on Mongolia and its implementation of the Nagoya Protocol here.